Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs National Beverage Corp. (FIZZ) Price & Performance

Quest Diagnostics IncTrade
National Beverage Corp.Trade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs National Beverage Corp. — how do they compare? Quest Diagnostics Inc trades at $205.48 (market cap $22.80B), while National Beverage Corp. trades at $31.01 (market cap $2.89B). The key difference: Quest Diagnostics Inc is far larger — about 7.9× National Beverage Corp.'s market cap, and Quest Diagnostics Inc pays a 1.67% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals.

DGXFIZZ
Market Cap
$22.80B$2.89B
Sector
HealthConsumer Cyclical
52-Week High
$216.02$47.69
52-Week Low
$166.42$30.92
Enterprise Value
$28.82B$2.60B
Dividend Yield
1.67%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.

DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.

National Beverage Corp.

FIZZ (National Beverage Corp.) trades at $31.13, down 7.95% over 24 hours, with a bearish technical signal and recent earnings misses in three of the last four quarters. The company reported $1.2B revenue and $186.82M net income for 2025, with strong profitability margins but a negative net cash flow of $133.21M. A special dividend of $3.25 per share was declared, payable July 30, 2026, providing a near-term catalyst.

Outlook is mixed: strong fundamentals and dividend support value, but technical weakness and earnings misses signal caution. Risks include competitive pressures and consumer spending trends. Analyst consensus is cautious with 50% sell ratings. The stock presents a high-risk opportunity for dividend-focused investors amid volatility.

Returns comparison

Trailing returns across standard periods

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About National Beverage Corp.

National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.

Read more on FIZZ